Chegg (ticker: CHGG), the educational software provider, saw its shares surge by 18% to $10.52 following the announcement of an accelerated share repurchase agreement worth $150 million. With a market cap of over $1 billion, the company is poised to further enhance shareholder value.
A Strong Position for Growth
Chegg CEO Dan Rosensweig expressed his excitement about the opportunities ahead, emphasizing Chegg's commitment to becoming the most impactful, AI-enabled, personal learning assistant globally. This unprecedented growth is made possible by the company's ability to generate strong free cash flow.
As of September 30, Chegg boasted $261 million in cash and short-term investments. Moreover, they held an additional $413 million in long-term investments, for a combined total of $674 million. This robust financial position allowed Chegg to reduce their convertible note position by approximately $589 million in the last nine months.
Strengthening the Repurchase Program
With the accelerated share repurchase, Chegg has effectively utilized $2.2 billion of their securities repurchase program, which encompasses both stock and convertible notes. Currently, $3.7 million remains on their outstanding securities buyback plan, which was expanded by $200 million in August.
Energizer Stock Downgraded Amid Weak Guidance
Tesla's New Toy: Cyberquad for Kids
Our Latest News
The Biden Administration Introduces New Student Loan Repayment Plan
The Biden administration has launched the SAVE Plan, an income-driven repayment plan to reduce monthly student loan payments for eligible borrowers. This plan c...
Tesla's Second-Quarter Earnings Report: What to Expect
Tesla's Q2 earnings report is highly anticipated with soaring stock performance and focus on profit margins. Analysts predict strong operating income and sales,...
Promising New Data Shows Positive Effect of Alterity Therapeutics' Parkinson's Disease Treatment in Monkeys
Alterity Therapeutics' treatment for Parkinson's disease demonstrates positive effects and reduction in iron levels in monkeys, validating ongoing clinical tria...